The delay accommodates Mr. Mahoney’s post-employment obligations with J&J. He replaces Boston Scientific CEO Ray Elliott, who announced in May that he intended to step down.
Hank Kucheman, currently the executive vice president and group president of the cardiology, rhythm and vascular group at Boston Scientific, will serve as interim CEO until Mr. Mahoney can assume the role full time in fall 2012.
Related Articles on Boston Scientific:
FDA May Revoke Approvals of Transvaginal Mesh Products
Boston Scientific Warns Patients of Non-Sterile, Stolen Devices
Boston Scientific Recalls Stent for Foreign Customers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
